Innovent Biologics' (HKG:1801) Sintbilo and Olverembatinib have been included in China's National Reimbursement Drug List, officially effective Jan. 1, 2025, a Thursday bourse filing said.
Sintbilo has been newly listed for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia.
The first indication of olverembatinib was renewed while a new indiation was also included in the list. The drug is now included in the list for the treatment of adult patients with chronic- or accelerated-phase chronic myeloid leukemia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。